Literature DB >> 12783108

Viral hemorrhagic fever--a vascular disease?

Hans-J Schnittler1, Heinz Feldmann.   

Abstract

The syndrome of "viral hemorrhagic fever" in man caused by certain viruses, such as Ebola, Lassa, Dengue, and Crimean-Congo hemorrhagic fever viruses, is often associated with a shock syndrome of undetermined pathogenesis. However, the vascular system, particularly the vascular endothelium, seems to be directly and indirectly targeted by all these viruses. Here we briefly summarize the current knowledge on Marburg and Ebola virus infections, the prototype viral hemorrhagic fever agents, and formulate a working hypothesis for the pathogenesis of viral hemorrhagic fever. Infections with filoviruses show lethality up to 89% and in severe cases lead to a shock syndrome associated with hypotension, coagulation disorders and an imbalance of fluid distribution between the intravascular and extravascular tissue space. The primary target cells for filoviruses are mononuclear phagocytotic cells which are activated upon infection and release certain cytokines and chemokines. These mediators indirectly target the endothelium and are thought to play a key role in the pathogenesis of filoviral hemorrhagic fever. In addition, direct infection and subsequent destruction of endothelial cells might contribute to the pathogenesis. Filoviruses, particularly Ebola virus, encode nonstructural glycoproteins which are released from infected host cells. Their function as potential determinants in pathogenicity remains to be investigated.

Entities:  

Mesh:

Year:  2003        PMID: 12783108

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  59 in total

1.  Crimean-Congo hemorrhagic fever virus activates endothelial cells.

Authors:  Anne-Marie Connolly-Andersen; Guido Moll; Cecilia Andersson; Sara Akerström; Helen Karlberg; Iyadh Douagi; Ali Mirazimi
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function.

Authors:  Victoria M Wahl-Jensen; Tatiana A Afanasieva; Jochen Seebach; Ute Ströher; Heinz Feldmann; Hans-Joachim Schnittler
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Arrestins in host-pathogen interactions.

Authors:  Stefano Marullo; Mathieu Coureuil
Journal:  Handb Exp Pharmacol       Date:  2014

4.  Expression of the infectious salmon anemia virus receptor on atlantic salmon endothelial cells correlates with the cell tropism of the virus.

Authors:  Maria Aamelfot; Ole Bendik Dale; Simon Chioma Weli; Erling Olaf Koppang; Knut Falk
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

5.  Coagulopathy parameters in patients with Crimean-Congo hemorrhagic fever and its relation with mortality.

Authors:  P Onguru; S Dagdas; H Bodur; M Yilmaz; E Akinci; S Eren; G Ozet
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

6.  Interacting roles of immune mechanisms and viral load in the pathogenesis of crimean-congo hemorrhagic fever.

Authors:  Ana Saksida; Darja Duh; Branka Wraber; Isuf Dedushaj; Salih Ahmeti; Tatjana Avsic-Zupanc
Journal:  Clin Vaccine Immunol       Date:  2010-05-19

Review 7.  Plasma leakage in dengue haemorrhagic fever.

Authors:  Anon Srikiatkhachorn
Journal:  Thromb Haemost       Date:  2009-12       Impact factor: 5.249

Review 8.  Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis.

Authors:  Karla Soares-Weiser; Sherine Thomas; Gail Thomson; Paul Garner
Journal:  BMC Infect Dis       Date:  2010-07-13       Impact factor: 3.090

9.  Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever.

Authors:  Brian B Gowen; Justin G Julander; Nyall R London; Min-Hui Wong; Deanna Larson; John D Morrey; Dean Y Li; Mike Bray
Journal:  Virol J       Date:  2010-09-16       Impact factor: 4.099

10.  Development of a new tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog.

Authors:  Brian B Gowen; Min-Hui Wong; Deanna Larson; Wei Ye; Kie-Hoon Jung; Eric J Sefing; Ramona Skirpstunas; Donald F Smee; John D Morrey; Stewart W Schneller
Journal:  PLoS One       Date:  2010-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.